Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
Objective: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. Methods: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2015-06-01
|
| Series: | Pharmacy Practice |
| Subjects: | |
| Online Access: | http://www.pharmacypractice.org/journal/index.php/pp/article/view/559/389 |
| _version_ | 1818496130376269824 |
|---|---|
| author | Okumura LM Antunes VD Aguiar KS Farias T Andrzejevski VM Funke VM |
| author_facet | Okumura LM Antunes VD Aguiar KS Farias T Andrzejevski VM Funke VM |
| author_sort | Okumura LM |
| collection | DOAJ |
| description | Objective: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients.
Methods: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confirmed during pharmacists’ consultation (patient-reported adherence). Baseline characteristics between groups were compared between cases and controls groups. Risk factors identified in bivariate analysis (p<0.2) were included in multivariate model. A qualitative investigation assessed whether such predictors of non-adherence had causal relationship.
Results: Of 151 patients with CML consulted by pharmacists, 21% had adherence problems. Despite patients with secondary school (p=0.03), most of investigated social risk factors did not differ between groups. However, by using a qualitative approach, patients’ level of education could not explain low adherence rates behavior.
Conclusions: Social determinants of health, herein investigated, were unlikely to predict adherence to treatment. Regression techniques may lead to untrue statements, so future researches should consider investigating the causes, not only the statistical estimates. |
| first_indexed | 2024-12-10T18:29:23Z |
| format | Article |
| id | doaj.art-82684f9883774e96b8b16b0f43878b04 |
| institution | Directory Open Access Journal |
| issn | 1885-642X 1886-3655 |
| language | English |
| last_indexed | 2024-12-10T18:29:23Z |
| publishDate | 2015-06-01 |
| publisher | Centro de Investigaciones y Publicaciones Farmaceuticas |
| record_format | Article |
| series | Pharmacy Practice |
| spelling | doaj.art-82684f9883774e96b8b16b0f43878b042022-12-22T01:37:58ZengCentro de Investigaciones y Publicaciones FarmaceuticasPharmacy Practice1885-642X1886-36552015-06-01132559559Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatmentOkumura LMAntunes VDAguiar KSFarias TAndrzejevski VMFunke VMObjective: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. Methods: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confirmed during pharmacists’ consultation (patient-reported adherence). Baseline characteristics between groups were compared between cases and controls groups. Risk factors identified in bivariate analysis (p<0.2) were included in multivariate model. A qualitative investigation assessed whether such predictors of non-adherence had causal relationship. Results: Of 151 patients with CML consulted by pharmacists, 21% had adherence problems. Despite patients with secondary school (p=0.03), most of investigated social risk factors did not differ between groups. However, by using a qualitative approach, patients’ level of education could not explain low adherence rates behavior. Conclusions: Social determinants of health, herein investigated, were unlikely to predict adherence to treatment. Regression techniques may lead to untrue statements, so future researches should consider investigating the causes, not only the statistical estimates.http://www.pharmacypractice.org/journal/index.php/pp/article/view/559/389Medication AdherenceRisk FactorsLeukemia MyeloidProtein Kinase InhibitorsQualitative ResearchBrazil |
| spellingShingle | Okumura LM Antunes VD Aguiar KS Farias T Andrzejevski VM Funke VM Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment Pharmacy Practice Medication Adherence Risk Factors Leukemia Myeloid Protein Kinase Inhibitors Qualitative Research Brazil |
| title | Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment |
| title_full | Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment |
| title_fullStr | Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment |
| title_full_unstemmed | Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment |
| title_short | Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment |
| title_sort | tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia defining the role of social risk factors and non adherence to treatment |
| topic | Medication Adherence Risk Factors Leukemia Myeloid Protein Kinase Inhibitors Qualitative Research Brazil |
| url | http://www.pharmacypractice.org/journal/index.php/pp/article/view/559/389 |
| work_keys_str_mv | AT okumuralm tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment AT antunesvd tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment AT aguiarks tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment AT fariast tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment AT andrzejevskivm tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment AT funkevm tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment |